The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma
Elisa Oricchio(Swiss Cancer Center Léman), Hans‐Guido Wendel(Memorial Sloan Kettering Cancer Center), Adriana Heguy, JoAnne Bruno(Cornell University), Juha P. Himanen(Memorial Sloan Kettering Cancer Center), Frances Weis‐Garcia(Memorial Sloan Kettering Cancer Center), Nicholas D. Socci, Gouri J. Nanjangud(Memorial Sloan Kettering Cancer Center), Andrew L. Wolfe(The Graduate Center, CUNY), Man Jiang(Memorial Sloan Kettering Cancer Center), Jonathan H. Schatz(University of Miami), Wayne Tam(Cornell University), Julie Teruya‐Feldstein(Memorial Sloan Kettering Cancer Center), Rita Shaknovich(Medical Research Council), Konstantinos J. Mavrakis(Bristol-Myers Squibb (Germany)), Xiaoping Liu(Inner Mongolia Medical University), Adam B. Olshen(University of California, San Francisco), R. S. K. Chaganti(Leukemia and Lymphoma Society), Ari Melnick(Cornell University)
Cited by 180
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Mutations in <i>GNA11</i> in Uveal Melanoma
|New England Journal of Medicine|2010|1.5k